La chaîne d'options affiche les données clés des options sur actions de Acurx Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Acurx Pharmaceuticals..

Acurx Pharmaceuticals (NASDAQ:ACXP) Stock, Chaîne d'Options

ACURX PHARMACEUTICALS INC

Acurx Pharmaceuticals

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals Inc

AMETEK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) has outperformed the market over the past 15 years by 4.17% on an annualized basis producing an average annual return of 16.17%. Currently, AMETEK has a market capitalization of $40.51 billion. 
Buying $1000 In AME: If an investor had bought $1000 of AME stock 15 years ago, it would be worth $9,449.46 today based on a price of $175.55 for AME at the time of writing.
<h3>AMETEK's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750198512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In AMETEK 15 Years Ago Would Be Worth This Much Today

Several professional athletes have announced taking salary or endorsement money in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) in recent years, <a href="https://www.benzinga.com/markets/cryptocurrency/21/07/21984141/nfls-saquon-barkley-to-take-100-of-endorsement-money-in-bitcoin">including NFL superstar</a> Saquon Barkley.
Here's a look back at his decision and how much investors could have made following the NFL star running back.
What Happened: Barkley, who won a Super Bowl with<a href="https://www.benzinga.com/general/sports-betting/24/03/37635003/super-bowl-betting-shakeup-how-top-nfl-signings-are-reshaping-the-odds"> the Philadelphia Eagles </a>last season, made a surprising announcement on July 14, 2021, when he announced he would take 100% of his endorsement money in Bitcoin.
The endorsement money was converted to Bitcoin via Strike, a Bitcoin payments company.
"You see inflation. You see how high it is right now," Barkley said at the time.
After missing time the previous season with an injury, Barkley discussed the dilemmas of having enough money in case his career was cut short.
"I'm gonna be taking my marketing money in Bitcoin," Barkley&nbsp;<a href="https://x.com/APompliano/status/1415354090645827590" target="_blank" rel="noreferrer noopener">announced&nbsp;</a>on "The Best Business Show With Anthony Pompliano."
When he entered the NFL, Barkley said his&nbsp;plan was to live off his marketing money and save his salary.
"This is the smart thing to do, the right thing to do."
Strike CEO Jack Mallers joined the show and said he was proud of Barkley for taking the step to preserve his wealth for himself and his family.
"His cash is going to be worth half as less in five years," Mallers said, citing inflation.
Mallers pointed out that the average NFL career is 3 1/2 years, providing financial uncertainties for athletes.
Barkley receives over $10 million in endorsements annually, <a href="https://twitter.com/JoePompliano/status/1415346064807366658" target="_blank" rel="noreferrer noopener">according </a>to Joe Pompliano, who was featured on the show.
Fast forward to 2025 and Barkley is proud of his decision and being able to silence the people who thought he was making a dumb decision.
"People are always gonna have something to say," Barkley <a href="https://x.com/coinbase/status/1933324509177577724">said </a>at the recent Coinbase State of Crypto Summit.
Barkley said the decision was made at the right time after talking with his manager, Mallers and Pompliano. Barkley also recalls that he had a phone call with Strategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) Executive Chairman Michael Saylor at the time.
"Back then, he told me I should take all my money and put it in, I think he's doing pretty well."
Barkley joked that maybe he should've listened to Saylor.
When it comes to finances and investment decisions, Barkley said he never wants to be the smartest person in the world.
"Surround yourself with super smart people."
Read Also: <a href="https://www.benzinga.com/25/02/43608426/super-bowl-lix-rematch-again-sportsbooks-list-eagles-chiefs-as-top-favorites-for-super-bowl-lx">Super Bowl LIX Rematch Again? Sportsbooks List Eagles, Chiefs As Top Favorites For Super Bowl LX</a>
Investing $1,000 in Bitcoin: Today, Barkley is one of the most followed and talked about NFL stars, topping the league in 2024 for regular season rushes and rushing yards and setting career highs for the NFL star.
Investors who were fans of Barkley may have decided to invest in Bitcoin based on the comments made by the NFL star at the time.
A $1,000 investment in Bitcoin at the daily high on July 14, 2021, could have purchased 0.0302 BTC. Today, that $1,000 investment would be worth $3,155.50, up 215.6%.
Compare that to a $1,000 investment in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500 and broader U.S. stock market. The same $1,000 invested in the SPY would be worth $1,362.37 today, up 36.2%.
Barkley's investment of his endorsement money in Bitcoin has significantly outperformed the S&amp;P 500.
What's Next: Barkley enters the 2025 NFL season with the Eagles, hoping to win a second straight Super Bowl.
The Eagles are the favorites to win Super Bowl LX with odds of +650 at the DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) sportsbook. Barkley is the favorite to win the Offensive Player of the Year award in the 2025 NFL season with odds of +650, which would be a second straight win for the Eagles RB.
Barkley will be hoping to escape the "Madden curse," which is often used to describe down years or injuries that happen to players who appear on the <a href="https://www.nfl.com/news/eagles-rb-saquon-barkley-s-reverse-hurdle-graces-cover-of-madden-nfl-26">cover </a>of the Madden video game.
The Eagles star is the cover athlete for the Madden NFL 26 cover from Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>). Barkley is on the cover doing his reverse hurdle move that he pulled off during a 2024 NFL season game and is also one of the few players to have a perfect 99 score in the game.
Barkley was recently named the number one player by sales for the 2024 season by the <a href="https://nflpa.com/partners/posts/things-to-know-about-the-2024-year-end-nflpa-top-50-player-sales-list#:~:text=Saquon%20Barkley%20claimed%20the%20retail,2017%20to%20finish%20No.%201.">NFLPA</a>, becoming the first running back to top the list since 2017. Barkley enters the 2025 season with high expectations and as one of the top players for fans.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45871245/exclusive-bitcoin-to-hit-200k-in-2025-15-say-yes-while-many-see-new-all-time-highs-coming">EXCLUSIVE: Bitcoin To Hit $200K In 2025? 15% Say Yes While Many See New All-Time Highs Coming</a></li>
</ul>
Photos: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Education

Sports

$BTC

DKNG

MSTR

If You Invested $1,000 In Bitcoin When NFL Star Saquon Barkley Took Endorsement Money In BTC, Here's How Much You'd Have Today

<a href="https://www.axios.com/2025/06/17/trump-situation-room-meeting-iran-israel-war">https://www.axios.com/2025/06/17/trump-situation-room-meeting-iran-israel-war</a>

General

iShares MSCI Israel Capped Investable Market Index Fund

'Trump speaks with Netanyahu after crucial meeting on Israel-Iran war'- Axios

<a href="https://www.axios.com/2025/06/17/senate-passes-genius-act-despite-crypto-corruption-concerns?utm_campaign=editorial&amp;utm_medium=social&amp;utm_source=twitter">https://www.axios.com/2025/06/17/senate-passes-genius-act-despite-crypto-corruption-concerns?utm_campaign=editorial&amp;utm_medium=social&amp;utm_source=twitter</a>

'Senate passes GENIUS Act despite crypto corruption concerns'- Axios

Looking into the current session, Cemex Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) shares are trading at $6.82, after a 1.16% drop. Over the past month, the stock decreased by 3.13%, but over the past year, it actually spiked by 6.57%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1750197618_0.png" alt="Past Year Chart" />

<h3>How Does Cemex P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Cemex has a lower P/E than the aggregate P/E of 21.62 of the Construction Materials industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750197618_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into Cemex Inc's Price Over Earnings

Morningstar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NASDAQ">MORN</a>) has outperformed the market over the past 10 years by 3.41% on an annualized basis producing an average annual return of 14.32%. Currently, Morningstar has a market capitalization of $12.87 billion. 
Buying $1000 In MORN: If an investor had bought $1000 of MORN stock 10 years ago, it would be worth $3,790.20 today based on a price of $300.79 for MORN at the time of writing.
<h3>Morningstar's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750197616_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MORN

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

<a href="https://www.wsj.com/livecoverage/stock-market-today-trump-tariffs-trade-war-06-17-2025/card/trump-sparing-tiktok-from-ban-with-another-deadline-extension-ZQVod1UzdEvomPuyYyle?mod=Searchresults_pos1&amp;page=1">https://www.wsj.com/livecoverage/stock-market-today-trump-tariffs-trade-war-06-17-2025/card/trump-sparing-tiktok-from-ban-with-another-deadline-extension-ZQVod1UzdEvomPuyYyle?mod=Searchresults_pos1&amp;page=1</a>

AMZN

ORCL

PINS

SNAP

'Trump Sparing TikTok From Ban With Another Deadline Extension'- WSJ

FCPT

Four Corners Property Trust Acquires An Olive Garden Property For $4.1M

<a href="https://www.cnn.com/2025/06/17/politics/kristi-noem-hostpital">https://www.cnn.com/2025/06/17/politics/kristi-noem-hostpital</a>

'Homeland Security Secretary Kristi Noem transported by ambulance to DC-area hospital, sources say'- CNN

Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) has outperformed the market over the past 10 years by 5.53% on an annualized basis producing an average annual return of 16.45%. Currently, Booking Holdings has a market capitalization of $172.50 billion. 
Buying $100 In BKNG: If an investor had bought $100 of BKNG stock 10 years ago, it would be worth $460.80 today based on a price of $5301.05 for BKNG at the time of writing.
<h3>Booking Holdings's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750195824_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BKNG

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) shares are trading lower in Tuesday&#8217;s after-hours session after the company announced a proposed private placement of <a href="https://www.benzinga.com/pressreleases/25/06/g45984139/bitdeer-announces-proposed-private-placement-of-us-300-0-million-of-convertible-senior-notes">convertible senior notes</a>.
What Happened: Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining company Bitdeer announced plans to offer $300 million of convertible senior notes due 2031 in a private placement to institutional buyers. The company plans to grant the initial purchasers a 13-day window to purchase up to an additional $45 million of the notes.
Bitdeer expects to use a portion of the proceeds to pay the cost of a zero-strike call option transaction and to pay the cash consideration for concurrent note exchange transactions that involve privately negotiated agreements with one or more holders of 8.5% convertible senior notes due 2029.
The remaining proceeds will be used for data center expansions and ASIC-based mining rig development and manufacturing.
Bitdeer had $215.6 million in cash and cash equivalents as of March 31, as well as a total crypto balance of $131.1 million.
Last week, Bitdeer said it mined 196 Bitcoin in May, up 18.1% month-over-month. The company ended the month with a self-mining hashrate of 13.6 EH/s.
&#8220;Further, in May, we sold and shipped approximately 1.6 EH/s of our SEALMINER A2s to external customers. Our A3 Series will also be released and available for pre-order very soon,&#8221; the company said last week.
BTDR Price Action: <a href="http://benzinga.com/quote/BTDR">Bitdeer shares</a> were down 6.38% in after-hours Tuesday, trading at $12..70 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/25/06/45978954/kraken-partners-with-alpaca-to-expand-crypto-trading-to-financial-institutions">Kraken Partners With Alpaca To Expand Crypto Trading To Financial Institutions</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45957098/coinbase-to-benefit-from-political-landscape-analyst-says-now-is-buying-opportunity">Coinbase To Benefit From Political Landscape, Analyst Says Now Is &#8216;Buying Opportunity&#8217;</a></li>
</ul>
Photo: Yalcin Sonat/Shutterstock.

Offerings

After-Hours Center

Movers

BTDR

Bitcoin Mining Stock Bitdeer Technologies Is Sliding After The Bell: What's Sparking The Sell-Off?

BREA

Brera Holdings Entered Into Subscription Agreement, To Sell 2.1M Class B Ordinary Shares

Earnings

BANX

CORRECTION: ArrowMark Financial Q1 EPS $0.58 Down From $0.70 YoY

<a href="https://www.wsj.com/business/retail/hasbro-trims-3-of-workforce-in-cost-cutting-push-2ac88b24?msockid=21c662101c496b42343370ae1de86aaa" title="https://www.wsj.com/business/retail/hasbro-trims-3-of-workforce-in-cost-cutting-push-2ac88b24?msockid=21c662101c496b42343370ae1de86aaa">https://www.wsj.com/business/retail/hasbro-trims-3-of-workforce-in-cost-cutting-push-2ac88b24?msockid=21c662101c496b42343370ae1de86aaa</a>

Hasbro Spokeswoman Says Hasbro Is Aligning Cost Structure With Long-Term Goals; Hasbro Job Cuts Amount to Roughly 150 Workers; Hasbro Cuts 3% of Workforce

CoStar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) has outperformed the market over the past 10 years by 3.61% on an annualized basis producing an average annual return of 14.53%. Currently, CoStar Group has a market capitalization of $33.69 billion. 
Buying $100 In CSGP: If an investor had bought $100 of CSGP stock 10 years ago, it would be worth $383.50 today based on a price of $79.89 for CSGP at the time of writing.
<h3>CoStar Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750194912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CSGP

Here's How Much You Would Have Made Owning CoStar Group Stock In The Last 10 Years

WIIM

MMA stock has given up its prior loss. Mixed Martial Arts Group shares were trading lower after the company announced the pricing of a $5 million underwritten public offering at $0.76 per share.

Transactions to generate $14 million of liquidity and reduce non-floorplan indebtedness by $15 million
Continues to focus on strengthening the balance sheet in support of long-term stability, improving operational performance of dealerships, and strategically divesting non-core assets
TAMPA, Fla., June 17, 2025 /PRNewswire/ -- Lazydays Holdings, Inc.&nbsp;("Lazydays" or the "Company") (NasdaqCM: GORV) today announced that it has executed amendments and waivers with its credit facility lender syndicate led by M&amp;T Bank and its mortgage lender, an affiliate of Coliseum Capital Management, that will help to enhance the Company's liquidity position and further fortify its financial foundation.
Under the terms of the transactions, Lazydays will retain approximately $14 million of proceeds resulting from its divestures of certain non-core dealerships and associated real estate, and repay approximately $15 million in non-floorplan indebtedness, reducing non-floorplan indebtedness to approximately $44 million and meaningfully lowering interest expense.
The contributing divestitures are as follows:
<ul>
<li>Divestiture of dealership in Mesa, AZ, which closed on May 30, 2025;</li>
<li>Divestiture of dealership and related real estate in Fort Pierce, FL, which closed on June 6, 2025;</li>
<li>Divestiture of dealership in&nbsp;Longmont, CO, which closed on June 13, 2025; and</li>
<li>Divestiture of dealership and related real estate in Las Vegas, NV, which is expected to close later this week.</li>
</ul>

GORV

Lazydays Executes Credit Amendments And Non-Core Dealership Divestitures To Generate $14M Liquidity, Reduce Non-Floorplan Debt By $15M

SHYF

The Shyft Group Receives Shareholders' Approval For Its Merger With Aebi Schmidt Group

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares increased by 8.8% to $0.3 during Tuesday's after-market session. The market value of their outstanding shares is at $18.8 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock rose 8.14% to $0.69. The market value of their outstanding shares is at $111.0 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares increased by 8.0% to $0.88. The company's market cap stands at $14.5 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) stock moved upwards by 7.77% to $0.97. The company's market cap stands at $14.7 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares moved upwards by 6.66% to $1.12. The market value of their outstanding shares is at $2.3 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock rose 6.36% to $0.33. The market value of their outstanding shares is at $1.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares decreased by 26.2% to $2.14 during Tuesday's after-market session. The market value of their outstanding shares is at $77.5 million. </li>
<li>Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) stock decreased by 16.76% to $3.08. The company's market cap stands at $204.8 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock decreased by 16.26% to $0.24. The company's market cap stands at $20.7 million. As per the press release, Q4 earnings came out today. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock decreased by 14.35% to $5.97. The market value of their outstanding shares is at $17.2 million. </li>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) shares declined by 8.28% to $0.75. The market value of their outstanding shares is at $17.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 6.89% to $4.8. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACXP

BMEA

CGTX

CRDF

EYEN

GOVX

HSDT

IBIO

IRWD

SLRX

XAIR

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Rain Enhancement (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIN#NASDAQ">RAIN</a>) shares moved upwards by 11.4% to $3.62 during Tuesday's after-market session. The company's market cap stands at $27.4 million. </li>
<li>Robin Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) stock moved upwards by 11.23% to $11.78. The market value of their outstanding shares is at $28.1 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) stock moved upwards by 6.66% to $3.04. The market value of their outstanding shares is at $103.7 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) shares increased by 6.21% to $0.21. The market value of their outstanding shares is at $25.4 million. </li>
<li>Westwater Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WWR#AMEX">WWR</a>) shares rose 6.04% to $0.6. The market value of their outstanding shares is at $46.1 million. </li>
<li>Knightscope (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) stock increased by 5.94% to $5.7. The market value of their outstanding shares is at $39.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>XCHG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) stock declined by 10.7% to $1.3 during Tuesday's after-market session. The company's market cap stands at $77.2 million. </li>
<li>Smart Powerr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREG#NASDAQ">CREG</a>) shares fell 8.2% to $0.27. The market value of their outstanding shares is at $6.7 million. </li>
<li>Globus Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBS#NASDAQ">GLBS</a>) shares fell 5.23% to $1.27. The company's market cap stands at $26.1 million. The company's, Q1 earnings came out yesterday. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) shares declined by 4.62% to $0.91. The company's market cap stands at $6.4 million. </li>
<li>Click Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) shares declined by 4.42% to $0.35. The company's market cap stands at $11.1 million. </li>
<li>Royalty Management Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMCO#NASDAQ">RMCO</a>) shares declined by 4.31% to $1.11. The market value of their outstanding shares is at $16.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLIK

CREG

GLBS

HTCO

KSCP

NEOV

RAIN

RBNE

RMCO

SGBX

12 Industrials Stocks Moving In Tuesday's After-Market Session

Press Releases

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

Power Metallic (TSX.V: PNPN) Secures Largest Saudi License Amid June 2025 Gold Surge – Material Gains & More Stocks Inside

PNPNF

PRSO

SNYR

TSXV:PNPN

VERV

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

180 Life Sciences

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

CEL-SCI

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Genprex

GT Biopharma

IN8bio

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kairos Pharma

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mainz Biomed

PharmaCyte Biotech

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Soligenix

Synaptogenix

Alaunos Therapeutics, Inc. - Common Stock

Comments

Acurx Pharmaceuticals

Acurx Pharmaceuticals (ACXP) Options

Acurx Pharmaceuticals (NASDAQ:ACXP) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL